Essex Bio-Tech repurchases 25,000 shares; treasury stock climbs to 2.09 million

Bulletin Express09-16

Essex Bio-Technology Limited carried out an on-market share buyback on 16 September 2026, acquiring 25,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$2.025 to HK$2.05 per share. The volume-weighted average price was approximately HK$2.039, bringing the total consideration to HK$50,975.

Following the transaction, the number of issued shares (excluding treasury shares) fell to 564.91 million, while treasury shares increased to 2.09 million. Total issued shares remained unchanged at 567.01 million. The latest repurchase represents 0.00443 % of the company’s issued share capital before the event.

Under the general mandate granted on 26 May 2026—which authorises repurchases of up to 56.70 million shares—Essex Bio-Tech has so far bought back 2.09 million shares, equivalent to 0.36896 % of the company’s issued shares at the mandate date. All repurchased shares are being held as treasury stock; none have been cancelled.

In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 October 2026. The board confirmed that the buyback complied with all applicable regulations and that all funds due have been duly received.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152387851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 17:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152387851","market":"us","top_or_hot":-1,"title":"Essex Bio-Tech repurchases 25,000 shares; treasury stock climbs to 2.09 million","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited carried out an on-market share buyback on 16 September 2026, acquiring 25,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$2.025 to HK$2.05 per share. The volume-weighted average price was approximately HK$2.039, bringing the total consideration to HK$50,975.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) fell to 564.91 million, while treasury shares increased to 2.09 million. Total issued shares remained unchanged at 567.01 million. The latest repurchase represents 0.00443 % of the company’s issued share capital before the event.</p>\n<p>Under the general mandate granted on 26 May 2026—which authorises repurchases of up to 56.70 million shares—Essex Bio-Tech has so far bought back 2.09 million shares, equivalent to 0.36896 % of the company’s issued shares at the mandate date. All repurchased shares are being held as treasury stock; none have been cancelled.</p>\n<p>In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 October 2026. The board confirmed that the buyback complied with all applicable regulations and that all funds due have been duly received.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Tech repurchases 25,000 shares; treasury stock climbs to 2.09 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Tech repurchases 25,000 shares; treasury stock climbs to 2.09 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-16 17:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited carried out an on-market share buyback on 16 September 2026, acquiring 25,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$2.025 to HK$2.05 per share. The volume-weighted average price was approximately HK$2.039, bringing the total consideration to HK$50,975.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) fell to 564.91 million, while treasury shares increased to 2.09 million. Total issued shares remained unchanged at 567.01 million. The latest repurchase represents 0.00443 % of the company’s issued share capital before the event.</p>\n<p>Under the general mandate granted on 26 May 2026—which authorises repurchases of up to 56.70 million shares—Essex Bio-Tech has so far bought back 2.09 million shares, equivalent to 0.36896 % of the company’s issued shares at the mandate date. All repurchased shares are being held as treasury stock; none have been cancelled.</p>\n<p>In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 October 2026. The board confirmed that the buyback complied with all applicable regulations and that all funds due have been duly received.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1152387851","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152387851","pubTimestamp":1789550008,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited carried out an on-market share buyback on 16 September 2026, acquiring 25,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$2.025 to HK$2.05...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"埃塞克斯生物技术公司回购 25,000 股股票；美国国库股攀升至209万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited carried out an on-market share buyback on 16 September 2026, acquiring 25,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$2.025 to HK$2.05 per share. The volume-weighted average price was approximately HK$2.039, bringing the total consideration to HK$50,975.\nFollowing the transaction, the number of issued shares (excluding treasury shares) fell to 564.91 million, while treasury shares increased to 2.09 million. Total issued shares remained unchanged at 567.01 million. The latest repurchase represents 0.00443 % of the company’s issued share capital before the event.\nUnder the general mandate granted on 26 May 2026—which authorises repurchases of up to 56.70 million shares—Essex Bio-Tech has so far bought back 2.09 million shares, equivalent to 0.36896 % of the company’s issued shares at the mandate date. All repurchased shares are being held as treasury stock; none have been cancelled.\nIn accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 October 2026. The board confirmed that the buyback complied with all applicable regulations and that all funds due have been duly received.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152387851","isCrawlerRequest":true}